US court sides with Astra on SEROQUEL
Drugs giant AstraZeneca has had a bad run of late so news that a US District Court has ruled that the formulation patent protecting its SEROQUEL XR blockbuster drug is valid will be most welcome.
Drugs giant AstraZeneca has had a bad run of late so news that a US District Court has ruled that the formulation patent protecting its SEROQUEL XR blockbuster drug is valid will be most welcome.
The US District Court for the District of New Jersey also ruled that generic drugs makers Anchen Pharmaceuticals, Osmotica Pharmaceutical, Torrent Pharmaceuticals, Torrent Pharma, Mylan Pharmaceuticals and Mylan have all infringed the SEROQUEL XR formulation patent. The SEROQUEL XR formulation patent expires in 2017.
The court decision. which only affects the US markets, follows a decision made in the UK on 22nd March 2012, which found the formulation patent protecting SEROQUEL XR to be invalid. In the Netherlands, however, on 7th March 2012, the District Court in The Hague found the formulation patent protecting SEROQUEL XR to be valid.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
JH
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.
-
'We face a £6m inheritance tax bill under Reeves's changes – it's sheer terror'
Thousands of families fear they’ll have no option but to look at selling their firms in a fire sale to pay inheritance tax bills, due to Rachel Reeves’s changes to business property relief
-
Millions of over 50s fear pension investment risk – how should you position your portfolio?
To de-risk or not to de-risk, that is the question. Act too late and you could face irreversible losses. Move too early and miss out on significant gains that could transform your retirement.